• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
  

PubMed=20041153; DOI=10.1371/journal.pone.0008461; PMCID=PMC2794539
Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A., Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G., Baguley B.C., Eccles M.R.
A gene expression signature of invasive potential in metastatic melanoma cells.
PLoS ONE 4:E8461-E8461(2009)

PubMed=23658559; DOI=10.3389/fgene.2013.00066; PMCID=PMC3647113
Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S., Finlay G.J., Shelling A.N., Baguley B.C.
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
Front. Genet. 4:66.1-66.6(2013)

PubMed=23755070; DOI=10.3389/fgene.2013.00097; PMCID=PMC3668138
Kim J.E., Leung E.Y., Baguley B.C., Finlay G.J.
Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines.
Front. Genet. 4:97.1-97.8(2013)

PubMed=24455489; DOI=10.3389/fonc.2013.00333; PMCID=PMC3888952
D'mello S.A.N., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H.F., Furneaux C.E., During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.
Evidence that GRIN2A mutations in melanoma correlate with decreased survival.
Front. Oncol. 3:333.1-333.9(2014)

PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249
Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J., Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S., Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: a valuable model for studying the impact of genetic diversity in melanoma.
Pigment Cell Melanoma Res. 34:136-143(2021)